Lani
11-17-2006, 03:49 AM
Ann N Y Acad Sci. 2006 Sep;1075:235-243. Links
Cell-free DNA and RNA in Plasma as a New Molecular Marker for Prostate and Breast Cancer.
Papadopoulou E,
Davilas E,
Sotiriou V,
Georgakopoulos E,
Georgakopoulou S,
Koliopanos A,
Aggelakis F,
Dardoufas K,
Agnanti NJ,
Karydas I,
Nasioulas G.
Molecular Biology Research Center HYGEIA Antonis Papayiannis, Kifissias Ave. and Erythrou Stavrou 4 Str., 15123 Maroussi, Athens, Greece. g.nasioul@hygeia.gr.
In this study, we examined several molecular markers in prostate and breast cancer patients and in normal individuals. The markers tested were: variations in the quantity of plasma DNA, glutathione-S-transferase P1 gene (GSTP1), Ras association domain family 1A (RASSF1A), and ataxia telangiectasia mutated (ATM) methylation status in plasma, carcinoembryonic antigen (CEA) and prostate-specific membrane antigen (PSMA) mRNA in peripheral blood mononuclear cells (PBMC) and plasma samples from prostate cancer patients. DNA quantification in plasma was performed using real-time PCR (RT-PCR). We assessed the methylation status of GSTP1 in plasma DNA using methylation-specific PCR (MSP) assay, while the methylation status of RASSF1A and ATM genes was examined by the MethyLight technology. RT-PCR analysis was used for the detection of mRNA, PSMA, and CEA. In 58.3% of newly diagnosed prostate cancer patients and 26.7% of prostate cancer patients under therapy, plasma DNA levels were increased. Additionally, 48.5% of breast cancer patients showed plasma DNA levels above the cutoff limit. GSTP1 Promotor hypermethylation was detectable in 75% of plasma samples obtained from patients with newly diagnosed prostate cancer and in 36.8% of patients under therapy, whereas 26% and 14% of the breast cancer patients tested were positive for RASSF1A and ATM methylation, respectively. The combination of DNA load and promotor methylation status identified 88% of prostate cancer patients and 54% of breast cancer patients. This study shows that free-circulating DNA can be detected in cancer patients compared with disease-free individuals, and suggests a new, noninvasive approach for early detection of cancer.
PMID: 17108217 [PubMed -
Cell-free DNA and RNA in Plasma as a New Molecular Marker for Prostate and Breast Cancer.
Papadopoulou E,
Davilas E,
Sotiriou V,
Georgakopoulos E,
Georgakopoulou S,
Koliopanos A,
Aggelakis F,
Dardoufas K,
Agnanti NJ,
Karydas I,
Nasioulas G.
Molecular Biology Research Center HYGEIA Antonis Papayiannis, Kifissias Ave. and Erythrou Stavrou 4 Str., 15123 Maroussi, Athens, Greece. g.nasioul@hygeia.gr.
In this study, we examined several molecular markers in prostate and breast cancer patients and in normal individuals. The markers tested were: variations in the quantity of plasma DNA, glutathione-S-transferase P1 gene (GSTP1), Ras association domain family 1A (RASSF1A), and ataxia telangiectasia mutated (ATM) methylation status in plasma, carcinoembryonic antigen (CEA) and prostate-specific membrane antigen (PSMA) mRNA in peripheral blood mononuclear cells (PBMC) and plasma samples from prostate cancer patients. DNA quantification in plasma was performed using real-time PCR (RT-PCR). We assessed the methylation status of GSTP1 in plasma DNA using methylation-specific PCR (MSP) assay, while the methylation status of RASSF1A and ATM genes was examined by the MethyLight technology. RT-PCR analysis was used for the detection of mRNA, PSMA, and CEA. In 58.3% of newly diagnosed prostate cancer patients and 26.7% of prostate cancer patients under therapy, plasma DNA levels were increased. Additionally, 48.5% of breast cancer patients showed plasma DNA levels above the cutoff limit. GSTP1 Promotor hypermethylation was detectable in 75% of plasma samples obtained from patients with newly diagnosed prostate cancer and in 36.8% of patients under therapy, whereas 26% and 14% of the breast cancer patients tested were positive for RASSF1A and ATM methylation, respectively. The combination of DNA load and promotor methylation status identified 88% of prostate cancer patients and 54% of breast cancer patients. This study shows that free-circulating DNA can be detected in cancer patients compared with disease-free individuals, and suggests a new, noninvasive approach for early detection of cancer.
PMID: 17108217 [PubMed -